We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Drugmakers Push Back Against Proposed Exclusion Criteria for Rare Esophageal Disease Trial
Drugmakers Push Back Against Proposed Exclusion Criteria for Rare Esophageal Disease Trial
Two drug companies are pushing back against proposed FDA guidance that would require drug sponsors to hold pre-trials to determine whether patients with a nasty form of esophageal swelling could benefit from an alternate therapy.